Compare AbbVie Inc (ABBV) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Nuscale Power Corporation — how do they compare? AbbVie Inc trades at $248.39 (market cap $441.94B), while Nuscale Power Corporation trades at $9.58 (market cap $4.06B). The key difference: AbbVie Inc is far larger — about 108.9× Nuscale Power Corporation's market cap, and AbbVie Inc pays a 2.77% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| ABBV | SMR | |
|---|---|---|
Market Cap | $441.94B | $4.06B |
Sector | Health | Utilities |
52-Week High | $263.58 | $53.43 |
52-Week Low | $197.38 | $7.59 |
Enterprise Value | $506.19B | $2.99B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
SMR stock trades at $9.55, up 4.03% today, with a bullish technical signal from moving averages. The company reported a net loss of $355.79M on $31.48M revenue in 2025, with negative profit margins. Recent news highlights regulatory progress for its small modular reactor technology and potential from AI data center power demand.
Outlook hinges on commercial deployment success; high risk from persistent losses and execution challenges, but Wall Street consensus price target of $10.50 suggests moderate upside. Investor sentiment is divided, with 50% of analysts rating Buy amid significant financial volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
